Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) Sets New 12-Month High – Still a Buy?

Recordati Industria Chimica E Farmaceutica S.P.A. (OTCMKTS:RCDTF)’s stock price reached a new 52-week high during trading on Saturday . The stock traded as high as $58.75 and last traded at $58.75, with a volume of 223 shares. The stock had previously closed at $55.88.

Analyst Upgrades and Downgrades

RCDTF has been the subject of several analyst reports. Kepler Capital Markets upgraded Recordati Industria Chimica E Farmaceutica from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 3rd. Barclays upgraded Recordati Industria Chimica E Farmaceutica from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 12th. Two analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy”.

Recordati Industria Chimica E Farmaceutica Price Performance

The company has a current ratio of 1.64, a quick ratio of 1.16 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $12.12 billion, a PE ratio of 22.23 and a beta of 0.23. The firm has a 50 day moving average price of $56.62 and a 200 day moving average price of $61.70.

Recordati Industria Chimica E Farmaceutica (OTCMKTS:RCDTF) last issued its earnings results on Wednesday, May 13th. The company reported $1.08 earnings per share for the quarter. The company had revenue of $834.86 million during the quarter. Recordati Industria Chimica E Farmaceutica had a net margin of 17.81% and a return on equity of 35.19%.

About Recordati Industria Chimica E Farmaceutica

Recordati Industria Chimica e Farmaceutica is an Italy‐based international pharmaceutical company engaged in the research, development, manufacturing and commercialization of therapeutic products. Established in 1926, the company has built a diversified portfolio that includes proprietary drugs, generics and orphan medicines, with a particular emphasis on treatments for rare diseases. Recordati’s product range spans cardiovascular, urology, endocrinology, dermatology and oncology therapies, as well as specialized formulations for genetic and metabolic disorders.

The company’s historical roots date back nearly a century, when it began as a family‐owned enterprise in Milan.